ArticleMedicine2025
Causal associations of single anthropometric measures and body shape with nonalcoholic fatty liver disease: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The associations between anthropometric measures and nonalcoholic fatty liver disease (NAFLD) risk have been investigated in observational studies, but results were inconsistent. This study conducted the first large-scale Mendelian randomization (MR) analyses to explore causal associations of single anthropometric measures and body shape derived from principal component analysis with the risk of NAFLD. This study utilized two-sample MR with genome-wide association study data from Europeans to investigate the causal relationship between anthropometric measures, body shape, and NAFLD. Body shape is defined by principal component analysis taken from 6 anthropometric measures (body mass index [BMI], weight, height, waist circumference [WC], hip circumference [HC], and waist-to-hip ratio [WHR]). Instrumental variables were single-nucleotide polymorphisms with P < 5 × 10-8, and data harmonization was performed. To assess result robustness, sensitivity analyses (MR-Egger, weighted median, leave-one-out analysis), and outlier detection (Mendelian Randomization Pleiotropy Residual Sum and Outlier) were conducted, alongside heterogeneity evaluation (Cochran Q test). Scatter and funnel plots were utilized to assess the exposure-outcome relationship and causal estimate consistency. The results of inverse-variance weighted analyses demonstrated that BMI (OR = 1.547, 95 CI% = 1.215-1.972, P < .001), weight (OR = 1.461, 95 CI% = 1.247-1.711, P < .001), WC (OR = 1.365, 95 CI% = 1.012-1.842, P = .042), HC (OR = 1.453, 95 CI% = 1.122-1.882, P = .005), WHR (OR = 2.765, 95 CI% = 1.931-3.957, P < .001), and WHR adjusted for BMI (OR = 2.226, 95 CI% = 1.639-3.024, P < .001) were positively related to NAFLD risk. In terms of body shape, the results of inverse-variance weighted (OR = 0.934, 95 CI% = 0.900-0.970, P < .001) and MR-Egger (OR = 0.890, 95 CI% = 0.810-0.978, P = .016) showed that PC3 (a tall, centrally obese body shape) was negatively associated with NAFLD. This study indicated that BMI, weight, WC, and HC were positively associated with NAFLD risk. WHR adjusted for BMI may be a more reliable predictor of NAFLD risk than WHR. A body shape related to tall individuals with centrally obese was inversely associated with NAFLD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.